Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analys
The efficacy and hypoglycaemia profile of icodec versus once-daily comparators was generally consistent across ONWARDS trials irrespective of background GLP-1RA and/or SGLT2i use.
Authors
- Tina Vilsbøll (ORCID: https://orcid.org/0000-0002-0456-6787)
- Monika Kellerer (ORCID: https://orcid.org/0000-0002-9834-5976)
- Ronald Goldenberg (ORCID: https://orcid.org/0000-0002-1788-3255)
- Stinne Byrholdt Søgaard (ORCID: https://orcid.org/0000-0002-1611-4585)
- Bharath Kumar
- Ariel Fu (ORCID: https://orcid.org/0009-0007-0220-5877)
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Novo Nordisk (Denmark) (DK)
- Marienhospital Stuttgart (DE)
- LMC Diabetes & Endocrinology (Canada) (CA)
- Novo Nordisk (India) (IN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1111/dom.16328
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Novo Nordisk